American Journal of Cardiology
Volume 102, Issue 12 , Pages 1663-1667 , 15 December 2008

Change in High-Density Lipoprotein Cholesterol and Incident Coronary Heart Disease in Apparently Healthy Male Physicians

  • Catherine Rahilly-Tierney, MD, MPH

      Affiliations

    • Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Office of Research and Development, Cooperative Studies Program, Department of Veterans Affairs, Boston, Massachusetts
    • Division of Aging, Brigham and Women's Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-232-9500, ext. 44201; fax: 857-364-4424
    • ,
  • Thomas S. Bowman, MD, MPH

      Affiliations

    • Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Office of Research and Development, Cooperative Studies Program, Department of Veterans Affairs, Boston, Massachusetts
    • Division of Aging, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Luc Djoussé, MD, DSc

      Affiliations

    • Division of Aging, Brigham and Women's Hospital, Boston, Massachusetts
    • Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Howard D. Sesso, ScD, MPH

      Affiliations

    • Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Office of Research and Development, Cooperative Studies Program, Department of Veterans Affairs, Boston, Massachusetts
    • Division of Aging, Brigham and Women's Hospital, Boston, Massachusetts
    • Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • J. Michael Gaziano, MD, MPH

      Affiliations

    • Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Office of Research and Development, Cooperative Studies Program, Department of Veterans Affairs, Boston, Massachusetts
    • Division of Aging, Brigham and Women's Hospital, Boston, Massachusetts

Received 24 June 2008 ,Revised 25 July 2008 ,Accepted 25 July 2008.

References 

  1. Belanger C, Buring JE, Cook N, Aberlein K, Goldhaber SZ, Gordon D, et al Final report on the aspirin component of the ongoing Physician's Health Study. N Engl J Med. 1989;10:1425–1505
  2. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta-carotene on incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–1149
  3. Sesso HD, Gaziano JM, VanDenBurgh M, Hennekens CH, Glynn RJ, Buring JE. Comparison of baseline characteristics and mortality experience of participants and non-participants in a randomized clinical trial: the Physician's Health Study. Control Clin Trials. 2002;23:686–702
  4. Scranton R, Sesso HD, Stampfer MJ, Levenson JW, Buring JE, Gaziano JM. Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men. Am Heart J. 2004;147:1033–1038
  5. Wilson PW, Anderson KM, Harris T, Kannel WB, Castelli WP. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol. 1994;49:M252–M257
  6. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, HDL cholesterol decrease with age in older men and women (The Rancho Bernardo Study 1984–1994). Circulation. 1997;96:37–43
  7. Garry PJ, Hunt WC, Koehler KM, VanderJagt DJ, Vellas BJ. Longitudinal study of dietary intakes and plasma lipids in healthy elderly men and women. Am J Clin Nutr. 1992;55:682–688
  8. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins. Lancet. 2005;366:1267–1278
  9. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–445
  10. Deedwania P, Stone PH, Merz NB, Cosin-Aguilar J, Koylan N, Luo D, et al Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115:700–707
  11. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease (The Framingham Study). Am J Med. 1977;62:707–714
  12. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels (The Framingham Study). JAMA. 1986;256:2835–2838
  13. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease (Four prospective American studies). Circulation. 1989;79:8–15
  14. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenBurgh M, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 1993;329:1829–1834
  15. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373–381
  16. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromsø Heart-Study: high-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977;1:965–968
  17. Perova NV, Organov RG, Williams DH, Irving SH, Abernathy JR, Deev AD, et al. Association of high-density-lipoprotein cholesterol with mortality and other risk factors for major chronic noncommunicable disease in samples of US and Russian men. Ann Epidemiol. 1995;5:179–185
  18. Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131:32–47
  19. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1986;74:1217–1225
  20. Svensvold I, Urdal P, Thürmer H, Tverdal A, Lund-Larsen PG, Foss OP. High-density lipoprotein cholesterol and coronary, cardiovascular, and all cause mortality among middle-aged Norwegian men and women. Eur Heart J. 1992;13:1155–1163
  21. Enger SC, Hjermann I, Foss OP, Helgeland A, Holme I, Leren P, et al. High density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective case-control study in middle-aged men of the Oslo study. Artery. 1979;5:170–181
  22. Shaten BJ, Kuller LH, Neaton JD. Association between baseline risk factors, cigarette smoking, and CHD mortality after 10.5 years (MRFIT Research Group). Prev Med. 1991;20:655–659
  23. Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med. 1986;15:254–273
  24. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target. JAMA. 2007;298:786–798
  25. Goldenberg I, Goldbourt U, Boyko V, Behar S, Reicher-Reiss H BIP Study Group. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 2006;97:466–471
  26. Weisweiler P. Plasma lipoproteins and lipase and lecithin: cholesterol acyltransferase activities in obese subjects before and after weight reduction. J Clin Endocrinol Metab. 1987;65:969–973
  27. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–328
  28. Burke V, Beilin LJ, Cutt HE, Mansour J, Williams A, Mori TA. A lifestyle program for treated hypertensives improved health-related behaviors and cardiovascular risk factors, a randomized controlled trial. J Clin Epidemiol. 2007;60:133–141
  29. Ellison RC, Zhang Y, Qureshi MM, Knox S, Arnett DK, Province MA Investigators of the NHLBI Family Heart Study. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J. 2004;147:529–535

 This work was supported by the Office of Research and Development, Cooperative Studies Program (CSP), Department of Veterans Affairs. Dr. Djoussé is Principal Investigator on Grant K01 HL-70444 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland. The PHS is supported by Grants CA-34944, CA-40360, and CA-097193 from the National Cancer Institute and Grants HL-26490 and HL-34595 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland.

 The authors had full access to the data and take responsibility for its integrity, and all authors have read and agree to the manuscript as written. Dr. Bowman reports consulting for Veroscience LLC. Dr. Gaziano reports that he currently or in the past 5 years has received investigator-initiated federal funding from the National Institutes of Health (National Cancer Institute, National Heart, Lung, and Blood Institute, NIA, NEI) and the VA (CSP) and nonfederal investigator-initiated funding from McNeil Consumer Products and Pliva; research support in the form of pills and or packaging from BASF, DMS Pharmaceuticals, and Wyeth Pharmaceuticals; and honoria from Bayer and Pfizer for speaking engagements; and has served as a consultant for McNeil Consumer Products and Wyeth Pharmaceuticals; and as expert witness for Merck, Nutraquest, and Glaxo Smith Kline.

PII: S0002-9149(08)01389-1

doi: 10.1016/j.amjcard.2008.07.055

American Journal of Cardiology
Volume 102, Issue 12 , Pages 1663-1667 , 15 December 2008

Article Tools